Haemophilus somnus cDNA and Antigen

Haemophilus somnus is a species of bacteria that causes a number of diseases in animals, including otitis media in cattle and respiratory disease in horses. The antigen associated with this bacterium is a surface-located outer membrane protein called HsP60. This protein is involved in binding host cells and is considered a key virulence factor.This bacterium is known to produce several surface antigens, including Hemagglutinin antigen, Surface antigen, Surface antigen D15, 31 kDa antigen, and 17 kDa surface antigen.

Hemagglutinin antigen is a protein that plays a crucial role in the attachment of the bacterium to host cells. Surface antigen and Surface antigen D15 are both protective antigens that have been shown to induce an immune response in animals. The 31 kDa antigen and 17 kDa surface antigen are also thought to be involved in host-pathogen interactions.

Understanding the role of these surface antigens is important for the development of effective vaccines and treatments for Haemophilus somnus infections in cattle. By targeting these antigens, researchers hope to create a more effective and targeted approach to preventing and treating these infections.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E.coli expression Vector), which are ready for production of the recombinant proteins.

The cDNA of Haemophilus somnus can be used in the production of a vaccine. This cDNA can be used to genetically engineer a recombinant antigen that can stimulate the production of protective antibodies against the pathogen. The antigen is then incorporated into a vaccine formulation and administered to animals. The vaccine can be used to protect animals and humans from the infections caused by this bacterium.